

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-13. (canceled).

14. (currently amended) A method for treating multiple myeloma by ~~of~~ both inhibiting proliferation of myeloma cells and suppressing bone resorption, comprising administering to a patient suffering from multiple myeloma and bone lesions a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof, and a pharmaceutically acceptable carrier or diluent.

15. (currently amended) The method for treating multiple myeloma by ~~of~~ both inhibiting proliferation of myeloma cells and suppressing bone resorption according to claim 14, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 1 to 20 mg per day.

16. (currently amended) The method for treating multiple myeloma by ~~of~~ both inhibiting proliferation of myeloma cells and suppressing bone resorption according to claim 14, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 3 to 10 mg per day.

17. (currently amended) The method for treating multiple myeloma by ~~of~~ both inhibiting proliferation of myeloma cells and suppressing bone resorption according to any one

AMENDMENT UNDER 37 C.F.R. §1.116
U.S. Appln. No. 09/869,122

Q64929

of claims 14-16, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally.

18.-21. (canceled).